

ASX Release

7 February 2020

Trading and Dividend Update

Sigma Healthcare (Sigma) confirms that it remains on target to deliver FY20 Underlying EBITDA guidance of approximately \$46-47 million (\$57-58 million including the benefit from the adoption of the new accounting standard AASB 16 Leases).

Despite this, one off costs associated with transforming our business will result in Sigma generating insufficient franking credits to pay a fully franked final dividend in respect of FY20. The franking credit position will be reviewed as we progress through FY21.

Sigma CEO and Managing Director Mark Hooper said “The depleted franking credit balance is a lag effect of the costs of transforming our business. Our underlying business is performing strongly, with FY20 financial results remaining on track. More importantly, we continue to expect accelerated underlying earnings growth in FY21 from our core business.”

Guidance for FY21 will be provided at our FY20 results announcement, which is now scheduled for Wednesday 25 March 2020.

For more information, please contact:

Gary Woodford
Corporate Affairs Manager
gary.woodford@sigmahealthcare.com.au
0417 399 204 | 03 9215 9632

Steve Dabkowski
Blue Dot Media
steve@bluedot.net.au
0419 880 486